Showing 971-980 of 20379 results for "".
Soccer Injuries and How to Treat Them
https://reachmd.com/programs/focus-on-sports-medicine/soccer-injuries-and-how-to-treat-them/3670/The sports hernia is one of the most difficult injuries to diagnose and treat in elite soccer players. Join host Dr. Sherwin Ho as he talks with Dr. Riley Williams, associate professor of orthopedic surgery at Weill Medical College and medical director for the New York Red Bulls professional soccerTreating Brain Tumors with Immunotherapy
https://reachmd.com/programs/advanced-treatments-innovations-mayo-clinic/treating-brain-tumors-with-immunotherapy/12028/With brain cancer presenting its own unique set of challenges, how can we be sure that immunotherapy is the right treatment option?Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
https://reachmd.com/programs/cme/enhancing-collaborative-care-in-retinal-diseases-a-focus-on-injection-therapies/37715/Explore strategies to improve retinal disease referrals and adherence to anti-VEGF therapy through interdisciplinary collaboration.Global Perspectives on Perioperative Immunotherapy in LA HNSCC
https://reachmd.com/programs/cme/global-perspectives-on-perioperative-immunotherapy-in-la-hnscc/36261/Global Perspectives on Perioperative Immunotherapy in LA HNSCCOptimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-ohcm-the-emerging-role-of-cardiac-myosin-inhibitors/33176/Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin InhibitorsRethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
https://reachmd.com/programs/cme/secondary-stroke-prevention-emerging-role-factor-xi-inhibition/50969/Preventing stroke is critical, but for many patients, the fear of uncontrolled bleeding stands in the way of anticoagulation. What if we didn’t have to choose? Explore the emerging role of Factor XI/XIa inhibition and how it may redefine the balance between thrombosis and hemostasis. You’ll break doIgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/Examine updated KDIGO 2025 IgAN guidelines and the new approach to managing proteinuria and slowing kidney function decline.Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
https://reachmd.com/programs/cme/redefining-immunotherapy-access-integrating-subcutaneous-checkpoint-inhibitors-across-solid-tumors/56117/How are SC immune checkpoint inhibitors changing care in solid tumors? Hear a physician–nurse interview and explore implications for your practice.Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
https://reachmd.com/programs/cme/safety-of-cdk46-inhibitors-anticipation-prevention-and-management-of-adverse-events/39799/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
https://reachmd.com/programs/cme/breaking-down-the-benchmarks-pivotal-data-on-first-line-cdk46-inhibitors/39798/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.